239 related articles for article (PubMed ID: 34446068)
1. MEN1 silencing aggravates tumorigenic potential of AR-independent prostate cancer cells through nuclear translocation and activation of JunD and β-catenin.
Luo Y; Vlaeminck-Guillem V; Baron S; Dallel S; Zhang CX; Le Romancer M
J Exp Clin Cancer Res; 2021 Aug; 40(1):270. PubMed ID: 34446068
[TBL] [Abstract][Full Text] [Related]
2. Men1 disruption in Nkx3.1-deficient mice results in AR
Teinturier R; Luo Y; Decaussin-Petrucci M; Vlaeminck-Guillem V; Vacherot F; Firlej V; Bonnavion R; Abou Ziki R; Gherardi S; Goddard I; Gadot N; Bertolino P; Le Romancer M; Zhang CX
Oncogene; 2021 Feb; 40(6):1118-1127. PubMed ID: 33323967
[TBL] [Abstract][Full Text] [Related]
3. Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression.
Mehraein-Ghomi F; Kegel SJ; Church DR; Schmidt JS; Reuter QR; Saphner EL; Basu HS; Wilding G
Prostate; 2014 May; 74(7):792-803. PubMed ID: 24647988
[TBL] [Abstract][Full Text] [Related]
4. p68/DdX5 supports β-catenin & RNAP II during androgen receptor mediated transcription in prostate cancer.
Clark EL; Hadjimichael C; Temperley R; Barnard A; Fuller-Pace FV; Robson CN
PLoS One; 2013; 8(1):e54150. PubMed ID: 23349811
[TBL] [Abstract][Full Text] [Related]
5. Coordinated action of hypoxia-inducible factor-1α and β-catenin in androgen receptor signaling.
Mitani T; Harada N; Nakano Y; Inui H; Yamaji R
J Biol Chem; 2012 Sep; 287(40):33594-606. PubMed ID: 22865883
[TBL] [Abstract][Full Text] [Related]
6. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
Dulinska-Litewka J; McCubrey JA; Laidler P
Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
[TBL] [Abstract][Full Text] [Related]
7. Menin Enhances Androgen Receptor-Independent Proliferation and Migration of Prostate Cancer Cells.
Kim T; Jeong K; Kim E; Yoon K; Choi J; Park JH; Kim JH; Kim HS; Youn HD; Cho EJ
Mol Cells; 2022 Apr; 45(4):202-215. PubMed ID: 35014621
[TBL] [Abstract][Full Text] [Related]
8. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
Schweizer L; Rizzo CA; Spires TE; Platero JS; Wu Q; Lin TA; Gottardis MM; Attar RM
BMC Cell Biol; 2008 Jan; 9():4. PubMed ID: 18218096
[TBL] [Abstract][Full Text] [Related]
9. Activation of β-Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer.
Patel R; Brzezinska EA; Repiscak P; Ahmad I; Mui E; Gao M; Blomme A; Harle V; Tan EH; Malviya G; Mrowinska A; Loveridge CJ; Rushworth LK; Edwards J; Ntala C; Nixon C; Hedley A; Mackay G; Tardito S; Sansom OJ; Leung HY
Cancer Res; 2020 Feb; 80(3):576-590. PubMed ID: 31719098
[TBL] [Abstract][Full Text] [Related]
10. A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression.
Karacosta LG; Foster BA; Azabdaftari G; Feliciano DM; Edelman AM
J Biol Chem; 2012 Jul; 287(29):24832-43. PubMed ID: 22654108
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of androgen receptor and β-catenin activity in prostate cancer.
Lee E; Madar A; David G; Garabedian MJ; Dasgupta R; Logan SK
Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15710-5. PubMed ID: 24019458
[TBL] [Abstract][Full Text] [Related]
13. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells.
Mehraein-Ghomi F; Basu HS; Church DR; Hoffmann FM; Wilding G
Cancer Res; 2010 Jun; 70(11):4560-8. PubMed ID: 20460526
[TBL] [Abstract][Full Text] [Related]
15. TUG1 knockdown inhibits the tumorigenesis and progression of prostate cancer by regulating microRNA-496/Wnt/β-catenin pathway.
Li G; Yang J; Chong T; Huang Y; Liu Y; Li H
Anticancer Drugs; 2020 Jul; 31(6):592-600. PubMed ID: 32427740
[TBL] [Abstract][Full Text] [Related]
16. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
17. JunD Is Required for Proliferation of Prostate Cancer Cells and Plays a Role in Transforming Growth Factor-β (TGF-β)-induced Inhibition of Cell Proliferation.
Millena AC; Vo BT; Khan SA
J Biol Chem; 2016 Aug; 291(34):17964-76. PubMed ID: 27358408
[TBL] [Abstract][Full Text] [Related]
18. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
Mulholland DJ; Read JT; Rennie PS; Cox ME; Nelson CC
Oncogene; 2003 Aug; 22(36):5602-13. PubMed ID: 12944908
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
[TBL] [Abstract][Full Text] [Related]
20. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis.
Chesire DR; Ewing CM; Gage WR; Isaacs WB
Oncogene; 2002 Apr; 21(17):2679-94. PubMed ID: 11965541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
